Alvotech's AVT80 Trial Shows Positive Results as Potential Biosimilar for Entyvio

Alvotech has announced positive results from a study comparing the efficacy of AVT80, a potential biosimilar to Entyvio, to the original drug. All primary endpoints of the study were met, showing similar efficacy, safety, tolerability, and pharmacokinetics between the two drugs in healthy individuals. The study was a randomized, double-blind trial that aimed to demonstrate the biosimilarity of AVT80 to Entyvio. Alvotech is developing AVT16, another potential biosimilar to Entyvio, and plans to file for regulatory approval.